Bliznakova 2007.

Study characteristics
Methods	11‐day N‐of‐1 randomised, double‐blind, cross‐over trial with 2 interventions: MPH placebo
Participants	Number of participants screened: 1 boy Number included: 1 Number of participants followed up: 1 Number of withdrawals: 1 Diagnosis of ADHD: ICD‐10 (predominantly hyperactive type) Age: 15 years IQ: not stated MPH‐naive: no Ethnicity: not stated Country: Germany Setting: not stated Comorbidity: not stated Comedication: not stated Other sociodemographics: 2 parents
Interventions	The participant was randomly assigned to MPH and placebo across 11 days Mean MPH dosage: not stated Administration schedule: not stated Duration of each medication condition: the condition was changed daily, but placebo was given for 6 days and MPH for 5 days Washout before trial initiation: not relevant Medication‐free period between interventions: none Titration period: none Treatment compliance: 100% according to Table 7
Outcomes	ADHD symptoms CTRS: rated daily Parent/Teacher Rating Scale: rated daily Non‐serious AEs Assessment of stomachaches (yes/no) daily
Notes	Sample calculation: yes Ethics approval: not stated Key conclusion of trial authors Double‐blind trial showed significant symptom reduction under the medication condition, which was also noted by the participant himself. Furthermore, towards the end of the trial, the somatic complaints were gone Exclusion of MPH non‐responders/children who have previously experienced AEs while taking MPH before randomisation: no Any withdrawals due to AEs: no Funding source: not stated Email correspondence with trial authors: December 2013. Emailed trial author to request information about missing data but received no response. Not possible to use data from this trial
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double‐blind
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double‐blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No Selection bias (e.g. titration after randomisation → exclusion of MPH non‐responders or placebo responders): no
Selective reporting (reporting bias)	Low risk	No indication of selective reporting